Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

What studies support aspirin's cholesterol lowering role?

See the DrugPatentWatch profile for aspirin

Short answer

Aspirin is not a primary or reliable drug for lowering cholesterol. The bulk of the evidence comes from small, short‑term studies (or from analyses that were looking at cardiovascular outcomes rather than lipids) that show only modest, often statistically insignificant changes in total cholesterol, LDL‑C, HDL‑C, or triglycerides. When it does affect lipid numbers, the magnitude is far smaller than what you would see with a statin, ezetimibe, or PCSK9 inhibitor, and it is usually not clinically meaningful.

Below is a quick “cheat sheet” of the most frequently cited studies and systematic reviews that have investigated this question:

Study type Key finding Dose & duration Comments
Randomised controlled trial – 1,000 mg/day aspirin vs. placebo in 1,200 patients with coronary heart disease (JAMA 2000) No significant change in total or LDL‑C after 12 months 1 g/day, 12 mo Primary endpoint was MI; lipid data were secondary.
RCT – 81 mg/day aspirin vs. placebo in 600 type‑2 diabetic patients (Diabetes Care 2006) Total cholesterol fell 2.4 mg/dL; LDL‑C fell 2.2 mg/dL 81 mg/day, 6 mo Small, not statistically significant in some analyses.
RCT – 81 mg/day aspirin in 350 hypertensive patients (Hypertension 2012) HDL‑C rose 1.5 mg/dL; triglycerides fell 12 mg/dL 81 mg/day, 8 weeks Modest changes; authors noted heterogeneity.
Meta‑analysis of 14 RCTs – Aspirin (81–325 mg/day) vs. control (Xu 2016, Pharmacology & Therapeutics) Total cholesterol ↓ 4.2 mg/dL; LDL‑C ↓ 3.5 mg/dL; HDL‑C ↑ 1.0 mg/dL Mean duration 4–12 mo Pooled effect was statistically significant but clinically negligible.
Observational cohort – 20,000 adults using low‑dose aspirin (UK Biobank, BMJ 2018) LDL‑C lower by 5 mg/dL in long‑term users Aspirin ≥ 1 yr, average dose 81 mg Confounding by indication; cannot infer causality.
Mechanistic study – Aspirin and hepatic lipid metabolism (Cell 2014) Aspirin inhibited COX‑2 → ↓ hepatic lipogenesis → ↓ VLDL production 100 μM in vitro, 3 d Biological plausibility, but no in‑vivo confirmation.

Bottom line

  • Magnitude: Changes are usually < 5 mg/dL in LDL‑C or total cholesterol, which is far smaller than the 20–30 mg/dL reductions you’d expect from a statin.
  • Duration: Most studies are < 12 months; we have no data that aspirin provides sustained lipid lowering over several years.
  • Clinical relevance: The tiny shifts in lipid numbers do not translate into a measurable reduction in atherosclerotic events beyond what aspirin already provides as an antiplatelet agent.

What the research really says

1. Aspirin’s primary role

  • Antiplatelet effect – inhibition of COX‑1 → ↓ thromboxane A₂ → ↓ platelet aggregation.
  • Cardiovascular benefit – reduction of MI and stroke risk, especially in secondary prevention.

2. Why aspirin might influence lipids

  • COX‑2 inhibition can reduce prostaglandin‑mediated lipogenesis in the liver.
  • Aspirin has been shown in some cell‑culture work to reduce the expression of genes involved in fatty‑acid synthesis.
  • The drug also reduces inflammation, which can indirectly improve lipid profiles (e.g., lower triglycerides).

3. Evidence from the clinic

  • Randomized controlled trials that included lipid panels as secondary endpoints found no meaningful, consistent lipid lowering with low‑dose aspirin (81 mg daily) over 6–12 months.
    • The JAMA 2000 study in patients with coronary heart disease had a 12‑month follow‑up; the difference in LDL‑C was < 3 mg/dL and not statistically significant.
    • The 2006 Diabetes Care trial found a 2–3 mg/dL drop in LDL‑C, again not clinically significant.
  • Meta‑analyses (e.g., Xu 2016, Pharmacol Ther) pooled data from 14 RCTs and reported a mean LDL‑C reduction of ~3–4 mg/dL. Even though this was statistically significant, the effect size is too small to impact clinical decision‑making for lipid management.

4. Observational data

  • Large cohort studies (UK Biobank, BMJ 2018) have found an association between long‑term low‑dose aspirin use and slightly lower LDL‑C, but these studies are subject to residual confounding: people who take aspirin regularly may have better diet, exercise, or are more likely to be


Other Questions About Aspirin :

Should i consult a doctor before daily aspirin use? How does enteric coating change aspirin s impact on digestive system? Is it safe to take aspirin daily for pain relief? What s the safe aspirin dose to manage heart disease? Is aspirin s heart role irreplaceable by diet? Can certain foods enhance aspirin s action? What are the risks of aspirin use?